CN102180832A - 脑缺血保护用化合物及制备方法 - Google Patents
脑缺血保护用化合物及制备方法 Download PDFInfo
- Publication number
- CN102180832A CN102180832A CN 201110065609 CN201110065609A CN102180832A CN 102180832 A CN102180832 A CN 102180832A CN 201110065609 CN201110065609 CN 201110065609 CN 201110065609 A CN201110065609 A CN 201110065609A CN 102180832 A CN102180832 A CN 102180832A
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- dihydro
- phenylformic acid
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 206010008118 cerebral infarction Diseases 0.000 title claims abstract description 33
- 201000006474 Brain Ischemia Diseases 0.000 title claims abstract description 26
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 13
- 241000723346 Cinnamomum camphora Species 0.000 claims description 13
- 229930008380 camphor Natural products 0.000 claims description 13
- 229960000846 camphor Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 235000002639 sodium chloride Nutrition 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 8
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 claims description 7
- UOBCZXSWQQWTGC-UHFFFAOYSA-N amino(phenyl)carbamic acid Chemical compound OC(=O)N(N)C1=CC=CC=C1 UOBCZXSWQQWTGC-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 230000001143 conditioned effect Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000012059 conventional drug carrier Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical class O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 abstract description 23
- 230000006378 damage Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 210000002569 neuron Anatomy 0.000 abstract description 7
- 230000002785 anti-thrombosis Effects 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000007971 neurological deficit Effects 0.000 abstract description 2
- 239000005711 Benzoic acid Substances 0.000 abstract 3
- 235000010233 benzoic acid Nutrition 0.000 abstract 3
- 208000022306 Cerebral injury Diseases 0.000 abstract 1
- 208000008457 Neurologic Manifestations Diseases 0.000 abstract 1
- 229950009041 edaravone Drugs 0.000 description 18
- 239000011734 sodium Substances 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 10
- 230000002490 cerebral effect Effects 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 7
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- ISOVWEWRUVBJME-UHFFFAOYSA-N 1,2,3-triphenyltetrazole Chemical class C1=NN(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 ISOVWEWRUVBJME-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 201000008247 brain infarction Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- -1 Edaravone Compound Chemical class 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical class OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110065609A CN102180832B (zh) | 2011-03-18 | 2011-03-18 | 脑缺血保护用化合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110065609A CN102180832B (zh) | 2011-03-18 | 2011-03-18 | 脑缺血保护用化合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102180832A true CN102180832A (zh) | 2011-09-14 |
CN102180832B CN102180832B (zh) | 2012-09-12 |
Family
ID=44567147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110065609A Expired - Fee Related CN102180832B (zh) | 2011-03-18 | 2011-03-18 | 脑缺血保护用化合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102180832B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301099A (zh) * | 2012-03-06 | 2013-09-18 | 江苏先声药物研究有限公司 | 2,4-二磺酰α-苯基叔丁基硝酮与2-莰醇的组合物 |
CN108314652A (zh) * | 2017-01-18 | 2018-07-24 | 周意 | 依达拉奉衍生物及其用途 |
CN110248649A (zh) * | 2017-07-07 | 2019-09-17 | 苏州沪云新药研发股份有限公司 | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 |
CN112755037A (zh) * | 2021-01-28 | 2021-05-07 | 南京缘聚医药科技有限公司 | Zl006和(+)2-崁醇的组合物及其药物用途 |
CN113845424A (zh) * | 2021-10-14 | 2021-12-28 | 南京医科大学 | 右崁醇酯类化合物及其药物用途 |
WO2023066162A1 (zh) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
CN116262118A (zh) * | 2021-12-14 | 2023-06-16 | 真奥金银花药业有限公司 | 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用 |
JP7464949B2 (ja) | 2019-12-31 | 2024-04-10 | 華南理工大学 | ボルネオールベースのポリマーならびにその調製方法および応用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524352A (zh) * | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
US20100216853A1 (en) * | 2007-06-21 | 2010-08-26 | Ronen Marmorstein | Methods and Compositions for Modulating P300/CBP Activity |
-
2011
- 2011-03-18 CN CN201110065609A patent/CN102180832B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100216853A1 (en) * | 2007-06-21 | 2010-08-26 | Ronen Marmorstein | Methods and Compositions for Modulating P300/CBP Activity |
CN101524352A (zh) * | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
Non-Patent Citations (1)
Title |
---|
《Redox Report》 20031231 Kazutoshi Watanabe et al Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) 第8卷, 第3期 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301099B (zh) * | 2012-03-06 | 2016-12-14 | 江苏先声药业有限公司 | 2,4‑二磺酰α‑苯基叔丁基硝酮与2‑莰醇的组合物 |
CN103301099A (zh) * | 2012-03-06 | 2013-09-18 | 江苏先声药物研究有限公司 | 2,4-二磺酰α-苯基叔丁基硝酮与2-莰醇的组合物 |
CN108314652A (zh) * | 2017-01-18 | 2018-07-24 | 周意 | 依达拉奉衍生物及其用途 |
WO2018133621A1 (zh) * | 2017-01-18 | 2018-07-26 | 周意 | 依达拉奉衍生物及其用途 |
CN110248649A (zh) * | 2017-07-07 | 2019-09-17 | 苏州沪云新药研发股份有限公司 | (+)-2-莰醇在制备促鞘氨醇激酶-1和/或bdnf表达上调的药物中的应用 |
JP7464949B2 (ja) | 2019-12-31 | 2024-04-10 | 華南理工大学 | ボルネオールベースのポリマーならびにその調製方法および応用 |
CN112755037A (zh) * | 2021-01-28 | 2021-05-07 | 南京缘聚医药科技有限公司 | Zl006和(+)2-崁醇的组合物及其药物用途 |
CN113845424A (zh) * | 2021-10-14 | 2021-12-28 | 南京医科大学 | 右崁醇酯类化合物及其药物用途 |
CN113845424B (zh) * | 2021-10-14 | 2023-09-12 | 南京医科大学 | 右崁醇酯类化合物及其药物用途 |
WO2023066162A1 (zh) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | 莰醇在制备治疗缺血性脑卒中的药物中的用途 |
CN116262118A (zh) * | 2021-12-14 | 2023-06-16 | 真奥金银花药业有限公司 | 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用 |
WO2023109513A1 (zh) * | 2021-12-14 | 2023-06-22 | 真奥金银花药业有限公司 | 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用 |
CN116262118B (zh) * | 2021-12-14 | 2024-03-29 | 真奥金银花药业有限公司 | 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102180832B (zh) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102180832B (zh) | 脑缺血保护用化合物及制备方法 | |
CN1578779B (zh) | 细胞增殖的有机小分子调节剂 | |
CN111511729A (zh) | Tlr7/8拮抗剂及其用途 | |
CN113181339B (zh) | 一种醛基类化合物的药物用途 | |
JP2024003097A (ja) | コロナウイルス感染の治療におけるファビピラビルの使用 | |
CN102807557B (zh) | 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用 | |
CN102153536A (zh) | 一种芒果苷元衍生物及其制备方法和用途 | |
CN105418601A (zh) | 四氢黄连碱衍生物及其应用 | |
CN102526036A (zh) | 一种含有丁苯酞和依达拉奉的复方注射液及制备方法 | |
CN105439883A (zh) | D-三七素的制备方法及其用途 | |
CN107298648B (zh) | 一类大黄酸硫代酰胺类化合物、其制备方法及用途 | |
CN110590779B (zh) | 3,10二对氯苯基6,12二氮杂四高立方烷类化合物及其合成方法、应用和药物组合物 | |
CN101658522B (zh) | 他克林短链二聚体类化合物在制备治疗神经退行性疾病药物中的应用 | |
CN101844994A (zh) | 阻断人免疫缺陷病毒入侵的棉酚氨基酸衍生物及制备方法和应用 | |
CN102204912A (zh) | 他克林或其衍生物在制备预防或治疗脑中风的药物中的应用 | |
CN101597276B (zh) | N-(α,β-二巯基-β-羧基丙酰基)-氨基酸的丙叉衍生物及其合成方法和应用 | |
CN105439889B (zh) | 一种香兰素胺类新化合物、其制备方法及医药用途 | |
CN111763139B (zh) | 银松素、银松素的用途及其制备方法 | |
CN115417844B (zh) | 一种环己乙醇化合物rengyolone及其制备方法与应用 | |
CN112999212B (zh) | 大麻二酚-3-磺酸在制备预防和/或治疗炎症相关疾病药物中的应用 | |
CN110684066B (zh) | 胞二磷胆碱药物制剂及其脑梗塞急性期意识障碍的新用途 | |
CN104230770A (zh) | 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用 | |
CN115300630B (zh) | 贝母生物碱类化合物在制备预防和/或治疗脑缺血导致的疾病的药物中的应用 | |
CN109438463B (zh) | 具有抗肿瘤活性的o-(4-溴-2-氟苯甲酰基)土甘草a、及制备方法和用途 | |
WO2023016495A1 (zh) | 含有白果内酯和大麻二酚的药物组合物及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Li Yunsen Document name: Notification that Application Deemed not to be Proposed |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI YUNSEN Effective date: 20150114 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215125 SUZHOU, JIANGSU PROVINCE TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: 215123, No. 5, building 5, C building, Dong Fang Pioneer Park, 1 Hua Yun Road, Suzhou, Jiangsu Patentee after: SUZHOU PHARMAVAN CANCER RESEARCH Co.,Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215125 No. 218 BioBAY A3 building room 203-204 Patentee before: SUZHOU PHARMAVAN CANCER RESEARCH Co.,Ltd. Patentee before: Li Yunsen |
|
C56 | Change in the name or address of the patentee |
Owner name: SUZHOU HUYUN TUMOUR RESEARCH CENTER CO., LTD. Free format text: FORMER NAME: SUZHOU PHAMAVAN CANCER RESEARCH CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 215123, building five, building 5, C zone, Dong Fang Industrial Park, 1 Hua Yun Road, Jiangsu, Suzhou Province Patentee after: SUZHOU PHARMAVAN CANCER RESEARCH CENTER Co.,Ltd. Address before: 215123, No. 5, building 5, C building, Dong Fang Pioneer Park, 1 Hua Yun Road, Suzhou, Jiangsu Patentee before: SUZHOU PHARMAVAN CANCER RESEARCH Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215123 5th floor, building 5, area C, Dongfang Industrial Park, No.1 Huayun Road, Suzhou Industrial Park, Jiangsu Province Patentee after: SUZHOU PHARMAVAN CANCER RESEARCH CENTER Co.,Ltd. Address before: 215123 5th floor, building 5, area C, Dongfang Industrial Park, No.1 Huayun Road, Suzhou Industrial Park, Jiangsu Province Patentee before: SUZHOU PHARMAVAN CANCER RESEARCH CENTER Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120912 |